Clinical Trial

SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single dose in healthy volunteers and multiple doses of SG301 SC injection in participants with systemic lupus erythematosus (SLE).
Protocol Amendment History 2 changes
critical Trial completed 2026-08-12
minor Completion moved earlier: 2026-10-24 -> 2026-01-07 2026-08-12
Trial Details
NCT Number NCT06144710
Lead Sponsor Hangzhou Sumgen Biotech Co., Ltd.
Conditions Systemic Lupus Erythematosus (SLE)
Enrollment 48 participants
Start Date 2023-11-10
Primary Completion 2026-01-07 (estimated)
Study Completion 2026-01-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-11